Progenics Pharmaceuticals, Inc. (PGNX) Reaches $5.75 After 6.00% Up Move; Sirius XM Holdings Inc. (SIRI) Covered By 9 Bullish Analysts Last Week

February 15, 2018 - By Henry Gaston

Among 17 analysts covering Sirius XM Holdings (NASDAQ:SIRI), 9 have Buy rating, 2 Sell and 6 Hold. Therefore 53% are positive. Sirius XM Holdings had 40 analyst reports since July 29, 2015 according to SRatingsIntel. Piper Jaffray maintained the shares of SIRI in report on Wednesday, October 11 with “Buy” rating. As per Thursday, October 22, the company rating was maintained by Pivotal Research. JP Morgan initiated the stock with “Neutral” rating in Monday, December 14 report. The firm has “Buy” rating by Buckingham Research given on Friday, February 2. The stock of Sirius XM Holdings Inc. (NASDAQ:SIRI) earned “Hold” rating by RBC Capital Markets on Monday, October 16. The stock has “Sector Perform” rating by RBC Capital Markets on Monday, October 26. The firm earned “Equal-Weight” rating on Wednesday, March 22 by Barclays Capital. RBC Capital Markets maintained it with “Hold” rating and $5.5 target in Thursday, January 11 report. Telsey Advisory Group maintained the shares of SIRI in report on Friday, February 3 with “Market Perform” rating. On Thursday, July 27 the stock rating was maintained by Piper Jaffray with “Buy”. See Sirius XM Holdings Inc. (NASDAQ:SIRI) latest ratings:

05/02/2018 Broker: Morgan Stanley Old Rating: Underweight New Rating: Underweight Old Target: $5.35 New Target: $5.5 Maintain
02/02/2018 Broker: Buckingham Research Old Rating: Buy New Rating: Buy Old Target: $6.5 New Target: $7 Maintain
01/02/2018 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $4.5 New Target: $5 Maintain
31/01/2018 Broker: RBC Capital Markets Rating: Hold New Target: $6.0 Maintain
19/01/2018 Broker: Buckingham Research Rating: Buy New Target: $6.5 Initiates Coverage On
19/01/2018 Broker: Deutsche Bank Old Rating: Hold New Rating: Buy Upgrade
11/01/2018 Broker: RBC Capital Markets Rating: Hold New Target: $5.5 Maintain
02/01/2018 Broker: Barrington Rating: Hold Downgrade
02/01/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Underweight Downgrade
18/12/2017 Broker: Morgan Stanley Rating: Sell

The stock of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) is a huge mover today! The stock increased 0.52% or $0.03 during the last trading session, reaching $5.75. About 252,675 shares traded. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has risen 48.41% since February 15, 2017 and is uptrending. It has outperformed by 31.71% the S&P500.The move comes after 8 months positive chart setup for the $404.05M company. It was reported on Feb, 15 by Barchart.com. We have $6.10 PT which if reached, will make NASDAQ:PGNX worth $24.24M more.

Investors sentiment decreased to 0.93 in Q3 2017. Its down 0.14, from 1.07 in 2017Q2. It dived, as 31 investors sold Sirius XM Holdings Inc. shares while 132 reduced holdings. 48 funds opened positions while 104 raised stakes. 884.13 million shares or 3.66% less from 917.75 million shares in 2017Q2 were reported. Hbk Sorce Advisory Ltd Liability Corporation holds 0.02% or 19,610 shares in its portfolio. Hollencrest Secs Ltd Liability Company has 10,525 shares for 0.01% of their portfolio. 180,647 were accumulated by Levin Capital Strategies L P. Sequoia Financial Advisors Ltd Com owns 0.01% invested in Sirius XM Holdings Inc. (NASDAQ:SIRI) for 11,800 shares. First Mercantile Commerce owns 0.05% invested in Sirius XM Holdings Inc. (NASDAQ:SIRI) for 49,570 shares. 108,206 were reported by Stifel Financial. Andra Ap stated it has 484,600 shares or 0.06% of all its holdings. 141,600 were accumulated by Pacad Invest Limited. Moreover, Cobblestone Cap Advsrs Ny has 0.11% invested in Sirius XM Holdings Inc. (NASDAQ:SIRI) for 167,883 shares. Gp One Trading L P invested in 0.01% or 246,895 shares. Cadence Capital Mgmt Limited Co has 54,887 shares. 36,400 are held by Fuller & Thaler Asset Mngmt. Sigma Planning stated it has 23,300 shares or 0.01% of all its holdings. The California-based Pure Financial Advisors has invested 0.02% in Sirius XM Holdings Inc. (NASDAQ:SIRI). Sumitomo Mitsui Asset holds 0.01% or 118,426 shares in its portfolio.

Sirius XM Holdings Inc. provides satellite radio services in the United States. The company has market cap of $27.27 billion. The firm broadcasts music plus sports, entertainment, comedy, talk, news, traffic, and weather programs, including various music genres ranging from rock, pop and hip-hop to country, dance, jazz, Latin, and classical; live play-by-play sports from principal leagues and colleges; multitude of talk and entertainment channels for various audiences; national, international, and financial news; and limited run channels. It has a 43.36 P/E ratio. It also streams music and non-music channels over the Internet; and offer applications to allow clients to access its Internet radio service on smartphones, tablets, computers, home devices, and other consumer electronic equipment.

The stock decreased 0.33% or $0.02 during the last trading session, reaching $6.07. About 5.01 million shares traded. Sirius XM Holdings Inc. (NASDAQ:SIRI) has risen 25.58% since February 15, 2017 and is uptrending. It has outperformed by 8.88% the S&P500.

Analysts await Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) to report earnings on March, 8. They expect $-0.21 EPS, down 110.00% or $0.11 from last year’s $-0.1 per share. After $-0.22 actual EPS reported by Progenics Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -4.55% EPS growth.

Among 5 analysts covering Progenics Pharm (NASDAQ:PGNX), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Progenics Pharm had 11 analyst reports since August 6, 2015 according to SRatingsIntel. The company was maintained on Thursday, August 6 by Brean Capital. Needham maintained the shares of PGNX in report on Friday, August 7 with “Buy” rating. The rating was maintained by Jefferies with “Buy” on Thursday, June 8. Jefferies maintained the shares of PGNX in report on Tuesday, September 26 with “Buy” rating. The stock has “Buy” rating by Jefferies on Friday, October 23. The company was downgraded on Friday, August 7 by Zacks. Cantor Fitzgerald maintained Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) rating on Wednesday, August 9. Cantor Fitzgerald has “Buy” rating and $1500 target. The rating was initiated by Aegis Capital with “Buy” on Thursday, October 27. Needham upgraded the shares of PGNX in report on Monday, February 6 to “Strong Buy” rating. On Tuesday, June 20 the stock rating was maintained by Needham with “Buy”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Henry Gaston

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: